TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20885412

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum twice a day after breakfast and lunch (G1)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum plus chlorhexidine varnish (G2)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish (G3)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Fluoride gel application (G4)
Number of subjects: 82
Study: 18163038

Group type: EXPERIMENTAL
Intervention: rTMS treatment for major depressive disorder (MDD)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: rTMS as a maintenance intervention for MDD (approximately 2 rTMS sessions/week)
Number of subjects: 2
Study: 15608043

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.25%
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.25%
Number of subjects: 99

Group type: COMPARATOR
Intervention: bupivacaine 0.25%
Number of subjects: 99
Study: 11883386

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 11245

Group type: COMPARATOR
Intervention: Diclofenac or Ketoprofen
Number of subjects: 11245
Study: 10712710

Group type: EXPERIMENTAL
Intervention: Incremental induction with sevoflurane (2,4,6,7%) in 100% O2 (group IC-O2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Induction with high concentration of sevoflurane in 100% O2 (group HC-O2)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Induction with high concentration of sevoflurane in a mixture of O2:N2O (50:50) (group HC-N2O)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 65
Study: 7488983

Group type: EXPERIMENTAL
Intervention: Electronic thermography
Number of subjects: 0
Study: 2021297

Group type: EXPERIMENTAL
Intervention: Carbamazepine (200 to 800 mg/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6122846

Group type: EXPERIMENTAL
Intervention: Freshly prepared penicillin-G solution administered as a bolus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Penicillin-G solution stored for a few hours
Number of subjects: 0
Study: 31907027

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with conventional rehabilitation treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional rehabilitation treatment alone
Number of subjects: 100
Study: 30232416

Group type: EXPERIMENTAL
Intervention: Circadian phase (biological evening)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circadian misalignment (12-h behavioral cycle inversion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circadian misalignment
Number of subjects: 0
Study: 28287803

Group type: EXPERIMENTAL
Intervention: Benefit-finding intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: SIM-PE (simplified psychoeducation)
Number of subjects: 96

Group type: COMPARATOR
Intervention: STD-PE (standard psychoeducation)
Number of subjects: 96
Study: 25201508

Group type: COMPARATOR
Intervention: Belief that quitting will benefit their children
Number of subjects: 981

Group type: COMPARATOR
Intervention: Education level (more than high school)
Number of subjects: 981

Group type: COMPARATOR
Intervention: Having children under age 3 years
Number of subjects: 981

Group type: COMPARATOR
Intervention: Prior quit attempt
Number of subjects: 981
Study: 22857752

Group type: EXPERIMENTAL
Intervention: HAL-induced fluorescence
Number of subjects: 102

Group type: COMPARATOR
Intervention: White light
Number of subjects: 102
Study: 20500899

Group type: EXPERIMENTAL
Intervention: Vernonia cinerea (VC) supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise with VC supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 17650659

Group type: EXPERIMENTAL
Intervention: Acupuncture of acupoints of the Stomach Meridian (bilateral Liangmen (ST 21), Huaroumen (ST 24), Tianshu (ST 25), Wailing (ST 26))
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group acupuncture of Back‐Shu and Front‐Mu points (bilateral Weishu (BL 21), Dachangshu (BL 25), Xiaochangshu (BL 27), Hegu (LI 4) with electrical stimulation)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Treatment group vs control group
Number of subjects: 51
Study: 16230048

Group type: EXPERIMENTAL
Intervention: Open-label eszopiclone (3mg)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Double-blind placebo (initially) then switched to open-label eszopiclone
Number of subjects: 360
Study: 11911518

Group type: EXPERIMENTAL
Intervention: Home-based traditional exercise group (TEG)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Home-based functional exercise group (FEG)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 47
Study: 10423054

Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study: 7750528

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette‐Guerin (BCG) immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance BCG using three weekly treatments at 6-month intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single 6-week course of BCG
Number of subjects: 0
Study: 2246098

Group type: EXPERIMENTAL
Intervention: Maharishi Amrit Kalash (MAK) tablets, twice daily for six weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo, twice daily for six weeks
Number of subjects: 48
Study: 7044881

Group type: EXPERIMENTAL
Intervention: Laser photocoagulation (0.5-1s pulses, 55-80 W power)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Laser photocoagulation
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 152
Study: 31492176

Group type: EXPERIMENTAL
Intervention: Digital diabetes diary app
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Support from health-care personnel
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Routine use of the app
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Utility of the app
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Digital and clinical distress
Number of subjects: 24
Study: 27791311

Group type: EXPERIMENTAL
Intervention: Topical minoxidil 5% solution
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Platelets rich plasma injections
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26491273

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 0
Study: 23392463

Group type: EXPERIMENTAL
Intervention: CD8 T-cell activation measured by CD38/HLA-DR expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD8 T-cell activation during viral suppression <50 copies per milliliter
Number of subjects: 0
Study: 24688618

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (education, pharmacotherapy monitoring, detecting and solving drug related problems)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard pharmaceutical services (dispensing medicines with or without counseling)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Number of subjects: 84
Study: 19363097

Group type: EXPERIMENTAL
Intervention: Self-rated health question asked before chronic conditions in Spanish interviews
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-rated health question asked after chronic conditions in Spanish interviews
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-rated health question asked in English interviews
Number of subjects: 0
Study: 17534745

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg b.i.d.
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16886928

Group type: EXPERIMENTAL
Intervention: Dipyridamole 0.142 mg/kg per min administered intravenously
Number of subjects: 20
Study: 15363419

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESI)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Intradiscal steroid injections (ISI)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESI) in patients with inflammatory end‐plate changes
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Discography with or without intradiscal steroid
Number of subjects: 232
Study: 11112935

Group type: EXPERIMENTAL
Intervention: Valpromide
Number of subjects: 15
Study: 8683189

Group type: EXPERIMENTAL
Intervention: Condition 1: 12 presentations of a 2‐s visual stimulus
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Condition 2: 12 short stimuli presentations accompanied by another event
Number of subjects: 50

Group type: COMPARATOR
Intervention: Condition 3: Infant-control procedure with repeated presentation of the same stimulus
Number of subjects: 50
Study: 1327657

Group type: EXPERIMENTAL
Intervention: 5g of creatine monohydrate, four or six times a day for 2 or more days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 5g of creatine monohydrate every 2 hours
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 6 x 5g of creatine monohydrate/day
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 17
Study: 3874037

Group type: EXPERIMENTAL
Intervention: Fluoxetine (30 or 60 mg) with ethanol (45 ml absolute alcohol per 70 kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (30 or 60 mg)
Number of subjects: 0
Study: 31679186

Group type: EXPERIMENTAL
Intervention: Emtricitabine (F)/TAF
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (current antiretroviral therapy)
Number of subjects: 31
Study: 31077827

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (induction)
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily (maintenance)
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Tofacitinib (any dosage)
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study: 28017170

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30mg·kg‐1)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Lidocaine (2mg·kg‐1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 26237643

Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional composite
Number of subjects: 60
Study: 23478193

Group type: EXPERIMENTAL
Intervention: EPs 7630 (3 × 30 drops/day for 24 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 200
Study: 21820770

Group type: EXPERIMENTAL
Intervention: Standard diet
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Immunomodulatory formula
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 167

Group type: COMPARATOR
Intervention: Overall results
Number of subjects: 167
Study: 19590475

Group type: EXPERIMENTAL
Intervention: Self-applied transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Nortriptyline (10 mg daily increment over 1 week to 50 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison between TENS and Nortriptyline
Number of subjects: 59
Study: 17334477

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg once a week for 6 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diphereline (3.75 mg 4 times every 28 days)
Number of subjects: 50
Study: 14973304

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg p.o. on day 1 and 80 mg p.o. on days 2 and 3
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11253520

Group type: EXPERIMENTAL
Intervention: Münster Posterior Doublerod‐System (MPDS)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: One-stage ventro-dorsal procedure in combination with VDS and MPDS
Number of subjects: 45
Study: 9477905

Group type: EXPERIMENTAL
Intervention: Amine fluoride dentifrice (1,400 ppm)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Sodium fluoride dentifrice (1,400 ppm)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 115
Study: 7886279

Group type: EXPERIMENTAL
Intervention: Trunk angle at 60 degrees
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Trunk angle at 90 degrees
Number of subjects: 16

Group type: COMPARATOR
Intervention: Trunk angle at 120 degrees
Number of subjects: 16
Study: 3367172

Group type: EXPERIMENTAL
Intervention: Study group (urged to have annual multiphasic health checkups)
Number of subjects: 10713

Group type: COMPARATOR
Intervention: Control group (nonurged subjects)
Number of subjects: 10713
Study: 30197040

Group type: EXPERIMENTAL
Intervention: Intradermal BCG vaccine prior to standard intravesical BCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tokyo-172 BCG strain
Number of subjects: 0
Study: 27998549

Group type: EXPERIMENTAL
Intervention: Formal handoff approach
Number of subjects: 5157

Group type: COMPARATOR
Intervention: Focused handoff process
Number of subjects: 5157
Study: 26210166

Group type: EXPERIMENTAL
Intervention: Intravenous fosaprepitant 150 mg (NK1 group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ondansetron 4 mg (ONS group)
Number of subjects: 38
Study: 24283179

Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (LNG‐IUD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) 20 mg/daily for ten days
Number of subjects: 40
Study: 21210812

Group type: EXPERIMENTAL
Intervention: Forensic DNA evidence presented without case context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forensic DNA evidence presented within the context of a criminal case
Number of subjects: 0
Study: 18080059

Group type: EXPERIMENTAL
Intervention: Naltrexone (Revia) or acamprosate (Campral) or both medications and/or placebos in combination with medical management (MM), with or without combined behavioral intervention (CBI)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1383

Group type: COMPARATOR
Intervention: CBI without MM or pills
Number of subjects: 1383

Group type: COMPARATOR
Intervention: Acamprosate
Number of subjects: 1383
Study: 17318795

Group type: EXPERIMENTAL
Intervention: Telmisartan (Telm) 80 mg + Rosiglitazone (RSG) 4 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amlodipine (Aml) 10 mg + Rosiglitazone (RSG) 4 mg
Number of subjects: 40
Study: 14706485

Group type: EXPERIMENTAL
Intervention: Active mobile phone exposure
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 12
Study: 10673490

Group type: EXPERIMENTAL
Intervention: Condom promotion intervention
Number of subjects: 1382

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1382
Study: 9175946

Group type: EXPERIMENTAL
Intervention: 97% light filtering goggles for a minimum of four weeks or until the infant reached 31 weeks postmenstrual age
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 97% light filtering goggles
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study: 1532336

Group type: EXPERIMENTAL
Intervention: Twice weekly amorolfine 5% nail lacquer
Number of subjects: 456

Group type: COMPARATOR
Intervention: Once weekly amorolfine 5% nail lacquer
Number of subjects: 456
Study: 4065179

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) + danazol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aminoglutethimide (AG) alone
Number of subjects: 0
Study: 31566843

Group type: EXPERIMENTAL
Intervention: 8-week interval group
Number of subjects: 330

Group type: COMPARATOR
Intervention: 12-week interval group
Number of subjects: 330
Study: 29659913

Group type: EXPERIMENTAL
Intervention: Hydromorphone (4 mg/day initially, adjusted as necessary)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Oxycodone hydrochloride (10 mg/day initially, adjusted as necessary)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 183
Study: 27801825

Group type: EXPERIMENTAL
Intervention: Food supplement containing 600 mg of α‐lipoic acid, 165 mg of L‐carnosin, 7.5 mg of zinc, and vitamins of group B
Number of subjects: 105
Study: 23212928

Group type: EXPERIMENTAL
Intervention: Online cognitive behavioral stress management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 23259414

Group type: EXPERIMENTAL
Intervention: Collagen membrane seeded with autologous gingival fibroblasts (CM+GF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Collagen membrane (CM)
Number of subjects: 11
Study: 19929980

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg/d, titrated to 300 mg/day)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ, 12.5 mg/d, titrated to 25 mg/day)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 426

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 426
Study: 18947161

Group type: EXPERIMENTAL
Intervention: Lidocaine-Ketorolac
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lidocaine-Placebo
Number of subjects: 55
Study: 16636232

Group type: EXPERIMENTAL
Intervention: IV recombinant tissue plasminogen activator (rt‐PA) 0.9 mg/kg
Number of subjects: 616

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 616
Study: 14675576

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus simvastatin (10, 20, 40, or 80 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin monotherapy (10, 20, 40, or 80 mg)
Number of subjects: 0
Study: 10807491

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Venlafaxine 375 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Maprotiline 150 mg/day
Number of subjects: 32
Study: 9085388

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Annual tuberculin testing plus isoniazid (INH) preventive therapy
Number of subjects: 0
Study: 8138865

Group type: EXPERIMENTAL
Intervention: Combined behavioral therapy (relaxation training, temperature biofeedback, cognitive training)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined behavioral therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Temperature biofeedback
Number of subjects: 41
Study: 3752471

Group type: EXPERIMENTAL
Intervention: Pulsator syringes
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiometer B 129 syringes
Number of subjects: 50
Study: 30222541

Group type: EXPERIMENTAL
Intervention: Programmed-fit using REM to NAL-NL2
Number of subjects: 24

Group type: COMPARATOR
Intervention: First-fit
Number of subjects: 24
Study: 26698911

Group type: EXPERIMENTAL
Intervention: Myo-inositol (2 g plus 200 μg folic acid twice a day)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (200 μg folic acid twice a day)
Number of subjects: 220
Study: 24945426

Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25OHD) concentrations
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Increase in ITA° value (reflectance colorimeter measurement of skin color)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Race/ethnicity prediction of 25OHD
Number of subjects: 307
Study: 23742728

Group type: EXPERIMENTAL
Intervention: donepezil 23 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: donepezil 10 mg/d
Number of subjects: 0
Study: 20826962

Group type: EXPERIMENTAL
Intervention: Etomidate 0.2 mg/Kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg/Kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thiopentone 5 mg/Kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/Kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (Etomidate, Midazolam, Thiopentone, Propofol)
Number of subjects: 60
Study: 18796471

Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg intravenous bolus after third unsuccessful shock)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0
Study: 16155274

Group type: EXPERIMENTAL
Intervention: 20 mg Zn/d
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: 5 mg Zn/d
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 14693308

Group type: EXPERIMENTAL
Intervention: Prefilled, disposable pen (FlexPen)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Vial/syringe
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 121
Study: 11949772

Group type: EXPERIMENTAL
Intervention: Balanced mixture (B)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Phenylalanine and tyrosine deficient mixture (PT‐)
Number of subjects: 12
Study: 10078604

Group type: EXPERIMENTAL
Intervention: Two doses of HAV vaccination (25 units) at 0 and 24 weeks (Group 1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Three doses of HAV vaccination (25 units) at 0, 2, and 24 weeks (Group 2)
Number of subjects: 55
Study: 7668311

Group type: EXPERIMENTAL
Intervention: Octreotide (2 micrograms/kg, subcutaneously, every 8 hours)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1869643

Group type: EXPERIMENTAL
Intervention: Controlled-release styrene-divinylbenzene polymer system containing benzoyl peroxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical lotion with freely dispersed benzoyl peroxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulations containing entrapped benzoyl peroxide
Number of subjects: 0
Study: 7267678

Group type: EXPERIMENTAL
Intervention: hydrotalcite/dimethicone suspension
Number of subjects: 36

Group type: COMPARATOR
Intervention: magnesium hydroxide/aluminum hydroxide suspension
Number of subjects: 36